Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Recent advances in addressing tuberculosis give hope for future

12.02.2020

NIH officials describe 'banner year'

In September 2018, the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, issued its Strategic Plan for Tuberculosis Research, which outlined research priorities to reduce and ultimately end the burden of tuberculosis (TB).


This is a scanning electron micrograph of Mycobacterium tuberculosis bacteria, which cause TB.

Credit: NIAID

TB is a bacterial disease that has claimed the lives of more than a billion people in the past two centuries. Now, a new "Perspective" in The Journal of Infectious Diseases by NIAID Director Anthony S. Fauci, M.D., and other Institute officials summarizes recent progress in improved TB diagnostics, therapeutic regimens and prevention approaches that made 2019 a "banner year" for TB research.

Therapeutics trials described by the NIAID authors include BRIEF TB/A5279, a Phase 3 clinical study demonstrating that a one-month course of two antibiotic drugs worked as well as a nine-month regimen of a single drug to prevent TB disease among adults and adolescents with HIV at risk of developing active TB.

In June 2019, NIAID and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, also part of NIH, launched the Phase 3 PHOENIx MDR-TB trial in 12 countries. PHOENIx MDR-TB (Protecting Households on Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients) will compare two oral regimens for preventing active TB in adults, teens and children who are at high risk of infection because they live with adults who have multidrug-resistant TB. "Results from this innovative study will inform new TB prevention guidelines to avert the pain, disability and death associated with MDR-TB," Dr. Fauci and his coauthors write.

Advances in TB vaccine development in 2019 included exciting preclinical and clinical results from several studies, the Perspective authors write. A study in macaques, in which the Bacille Calmette-Guerin (BCG) vaccine--the world's only licensed TB vaccine--was administered intravenously (IV) instead of by the standard intradermal route resulted in a dramatic increase in efficacy. The findings support further investigation of IV BCG administration in future human clinical trials. The authors described results of a Phase 2b trial of a candidate TB vaccine M72/AS01 (developed by GlaxoSmithKline) as "groundbreaking." The trial enrolled 3,575 volunteers in three countries and demonstrated 50% efficacy in preventing development of active pulmonary TB compared with placebo.

The challenge in 2020 and beyond is to build on the momentum generated by these recent accomplishments, the authors note. Still urgently needed are rapid, inexpensive and accurate point-of-care diagnostics; new and more effective drugs; and new and improved vaccines that prevent transition from latent infection to active TB disease or that prevent infection altogether. Achieving the end of TB within a generation is possible only through concerted, collective and collaborative efforts that involve government, academia, industry and civil society at all levels, the authors conclude.

###

ARTICLE: RW Eisinger et al. 2019: A banner year for tuberculosis research. The Journal of Infectious Diseases DOI: 10.1093/infdis/jiaa051 (2020).

WHO: NIAID Director Dr. Anthony S. Fauci is available to provide comment.

CONTACT: To schedule interviews, please contact Anne A. Oplinger, (301) 402-1663, aoplinger@niaid.nih.gov.

NIAID conducts and supports research--at NIH, throughout the United States, and worldwide--to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.

Media Contact

Anne A. Oplinger
aoplinger@niaid.nih.gov
301-402-1663

 @NIAIDNews

http://www.niaid.nih.gov 

Anne A. Oplinger | EurekAlert!
Further information:
http://dx.doi.org/10.1093/infdis/jiaa051

More articles from Health and Medicine:

nachricht Experiments in mice and human cells shed light on best way to deliver nanoparticle therapy for cancer
26.03.2020 | Johns Hopkins Medicine

nachricht Too much salt weakens the immune system
26.03.2020 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Junior scientists at the University of Rostock invent a funnel for light

Together with their colleagues from the University of Würzburg, physicists from the group of Professor Alexander Szameit at the University of Rostock have devised a “funnel” for photons. Their discovery was recently published in the renowned journal Science and holds great promise for novel ultra-sensitive detectors as well as innovative applications in telecommunications and information processing.

The quantum-optical properties of light and its interaction with matter has fascinated the Rostock professor Alexander Szameit since College.

Im Focus: Stem Cells and Nerves Interact in Tissue Regeneration and Cancer Progression

Researchers at the University of Zurich show that different stem cell populations are innervated in distinct ways. Innervation may therefore be crucial for proper tissue regeneration. They also demonstrate that cancer stem cells likewise establish contacts with nerves. Targeting tumour innervation could thus lead to new cancer therapies.

Stem cells can generate a variety of specific tissues and are increasingly used for clinical applications such as the replacement of bone or cartilage....

Im Focus: Artificial solid fog material creates pleasant laser light

An international research team led by Kiel University develops an extremely porous material made of "white graphene" for new laser light applications

With a porosity of 99.99 %, it consists practically only of air, making it one of the lightest materials in the world: Aerobornitride is the name of the...

Im Focus: Cross-technology communication in the Internet of Things significantly simplified

Researchers at Graz University of Technology have developed a framework by which wireless devices with different radio technologies will be able to communicate directly with each other.

Whether networked vehicles that warn of traffic jams in real time, household appliances that can be operated remotely, "wearables" that monitor physical...

Im Focus: Peppered with gold

Research team presents novel transmitter for terahertz waves

Terahertz waves are becoming ever more important in science and technology. They enable us to unravel the properties of future materials, test the quality of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

“4th Hybrid Materials and Structures 2020” takes place over the internet

26.03.2020 | Event News

Most significant international Learning Analytics conference will take place – fully online

23.03.2020 | Event News

MOC2020: Fraunhofer IOF organises international micro-optics conference in Jena

03.03.2020 | Event News

 
Latest News

3D printer sensors could make breath tests for diabetes possible

27.03.2020 | Power and Electrical Engineering

TU Bergakademie Freiberg researches virus inhibitors from the sea

27.03.2020 | Life Sciences

The Venus flytrap effect: new study shows progress in immune proteins research

27.03.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>